Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

  •   Table of Contents

Download Guidelines

Management of Medication Toxicity or Intolerance

Hepatic Events

Last Updated: April 27, 2017; Last Reviewed: April 27, 2017

References

  1. Aceti A, Pasquazzi C, Zechini B, De Bac C, Group L. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002;29(1):41-48. Available at http://www.ncbi.nlm.nih.gov/pubmed/11782588.
  2. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35(5):538-539. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15021321.
  3. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. J Int AIDS Soc. 2010;13:31. Available at http://www.ncbi.nlm.nih.gov/pubmed/20691049.
  4. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37(1):3-17. Available at http://www.ncbi.nlm.nih.gov/pubmed/23121117.
  5. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24(12):1732-1747. Available at http://www.ncbi.nlm.nih.gov/pubmed/15585441.
  6. Cotte L, Benet T, Billioud C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. J Hepatol. 2011;54(3):489-496. Available at http://www.ncbi.nlm.nih.gov/pubmed/21056493.
  7. Gray D, Nuttall J, Lombard C, et al. Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis. J Trop Pediatr. 2010;56(3):159-165. Available at http://www.ncbi.nlm.nih.gov/pubmed/19710246.
  8. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin Infect Dis. 2010;50(4):502-511. Available at http://www.ncbi.nlm.nih.gov/pubmed/20085465.
  9. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis. 2009;49(4):626-635. Available at http://www.ncbi.nlm.nih.gov/pubmed/19589079.
  10. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis. 2006;43(7):904-910. Available at http://www.ncbi.nlm.nih.gov/pubmed/16941375.
  11. McDonald C, Uy J, Hu W, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS. 2012;26(5):259-264. Available at http://www.ncbi.nlm.nih.gov/pubmed/22404426.
  12. McKoy JM, Bennett CL, Scheetz MH, et al. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug safety: an international journal of medical toxicology and drug experience. 2009;32(2):147-158. Available at http://www.ncbi.nlm.nih.gov/pubmed/19236121.
  13. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010;52(3):1143-1155. Available at http://www.ncbi.nlm.nih.gov/pubmed/20812358.
  14. Ouyang DW, Shapiro DE, Lu M, et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS . 2009;23(18):2425-2430. Available at http://www.ncbi.nlm.nih.gov/pubmed/19617813.
  15. Phillips E, Bartlett JA, Sanne I, et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013;62(2):e55-57. Available at http://www.ncbi.nlm.nih.gov/pubmed/23328091.
  16. Schouten JN, Van der Ende ME, Koeter T, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther. 2012;36(9):875-885. Available at http://www.ncbi.nlm.nih.gov/pubmed/22971050.
  17. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34 Suppl 1(Suppl 1):S21-33. Available at http://www.ncbi.nlm.nih.gov/pubmed/14562855.
  18. Van Dyke RB, Wang L, Williams PL, Pediatric ACTGCT. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198(11):1599-1608. Available at http://www.ncbi.nlm.nih.gov/pubmed/19000014.
  19. Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis. 2011;24(1):12-18. Available at http://www.ncbi.nlm.nih.gov/pubmed/21157331.
  20. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186(1):23-31. Available at http://www.ncbi.nlm.nih.gov/pubmed/12089658.
  21. Aurpibul L, Bunupuradah T, Sophan S, et al. Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children. Pediatr Infect Dis J. 2015;34(6):e153-158. Available at https://www.ncbi.nlm.nih.gov/pubmed/25970117.
  22. Strehlau R, Donati AP, Arce PM, et al. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naive and -experienced infants and children aged >/=3 months to <6 years. J Int AIDS Soc. 2015;18:19467. Available at http://www.ncbi.nlm.nih.gov/pubmed/26066346.
  23. Rutstein RM, Samson P, Fenton T, et al. for the PACTG 1020A Study Team. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatr Infect Dis J. 2015;34:162-167.
  24. Cobicistat (Tybost) [package insert]. Food and Drug Administration. 2014. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203094s000lbl.pdf.
  25. Sonderup MW, Maughan D, Gogela N, et al. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. AIDS . 2016;30(9):1483-1485. Available at https://www.ncbi.nlm.nih.gov/pubmed/26959511.

Download Guidelines